Who makes Stocrin 600 Reference-Efavirenz 600 Test?

Stocrin 600 Reference-Efavirenz 600 Test is developed by Center for Clinical Pharmacology Research Bdbeq S.A..

What development phase is Stocrin 600 Reference-Efavirenz 600 Test in?

Stocrin 600 Reference-Efavirenz 600 Test is FDA-approved (marketed).

Last reviewed 2026-05-13 · How we verify

Stocrin 600 Reference-Efavirenz 600 Test

Center for Clinical Pharmacology Research Bdbeq S.A. · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Stocrin 600 Reference-Efavirenz 600 Test
Sponsor	Center for Clinical Pharmacology Research Bdbeq S.A.
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efavirenz Comparative Bioavailability (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Stocrin 600 Reference-Efavirenz 600 Test CI brief — competitive landscape report
Stocrin 600 Reference-Efavirenz 600 Test updates RSS · CI watch RSS
Center for Clinical Pharmacology Research Bdbeq S.A. portfolio CI